Complete Filing Data
Theravance Biopharma, Inc. reported Operating Expenses of $111.07 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Theravance Biopharma, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | $105.9M | -$56.4M | -$55.2M | $872.1M | -$199.4M | -$278.0M | -$236.5M | -$215.5M | -$285.4M | -$190.7M | -$182.2M | -$237.0M | -$156.3M | -$9.6M |
| Revenue * | $107.5M | $64.4M | $57.4M | $51.3M | $55.3M | $71.9M | $73.4M | $60.4M | $15.4M | $48.6M | $42.1M | $11.7M | $226.0K | $130.1M |
| Operating Expenses | $111.1M | $111.3M | $113.5M | $143.3M | $313.1M | $369.5M | $325.3M | $299.1M | $275.5M | $229.1M | $224.0M | $244.2M | $156.5M | $139.7M |
| Operating Income Loss | -$3.6M | -$46.9M | -$56.0M | -$92.0M | -$257.8M | -$297.6M | -$251.9M | -$238.8M | -$260.1M | -$180.5M | -$181.9M | -$232.5M | -$156.3M | -$9.6M |
| Selling General And Administrative Expense | $73.7M | $69.2M | $70.1M | $67.1M | $99.3M | $108.5M | $106.1M | $97.1M | $95.6M | $84.5M | $90.2M | $71.6M | $35.9M | $25.7M |
| Research And Development Expense | $37.4M | $37.6M | $40.6M | $63.4M | $193.7M | $261.0M | $219.2M | $201.3M | $173.9M | $141.7M | $129.2M | $168.5M | $120.6M | $114.0M |
| Comprehensive Income Net Of Tax | $105.9M | -$56.3M | -$55.2M | $872.1M | -$199.5M | -$278.1M | -$236.1M | -$215.0M | -$285.9M | -$190.9M | -$182.2M | -$237.2M | -$156.3M | -$9.6M |
| Other Nonoperating Income Expense | $10.2M | $4.9M | $9.1M | $8.5M | $1.1M | $2.8M | $8.4M | $12.0M | $4.8M | $1.3M | $631.0K | $1.9M | $0.00 | $0.00 |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | $129.2M | -$44.6M | -$49.3M | -$92.8M | -$265.2M | -$303.3M | -$241.7M | -$226.1M | -$271.7M | -$180.6M | -$181.3M | -$230.7M | -$156.3M | -$9.6M |
| Income Tax Expense Benefit | $23.4M | $11.8M | $5.9M | $9.0K | -$151.0K | -$8.5M | -$5.2M | -$10.6M | $13.7M | $10.1M | $951.0K | $6.4M | $0.00 | $0.00 |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $54.0K | $72.0K | -$50.0K | -$15.0K | -$47.0K | -$98.0K | $311.0K | $567.0K | -$480.0K | -$183.0K | $12.0K | -$173.0K | $0.00 | |
| Interest Expense | $2.4M | $6.4M | $8.5M | $8.5M | $31.9M | $10.5M | $8.5M | $1.4M | $0.00 | $0.00 | ||||
| Income Taxes Paid Net | $27.9M | $109.0K | $24.0K | $118.0M | -$4.1M | $14.0K | $22.0K | -$7.3M | $4.9M | -$9.5M | $13.4M | $4.6M | ||
| Cost Of Goods Sold | $6.0M | $2.9M | $4.7M | $4.1M | $0.00 | $0.00 | ||||||||
| Income Loss From Continuing Operations Per Diluted Share | -$1.00 | -$1.26 | -$3.82 | -$4.73 | ||||||||||
| Income Loss From Continuing Operations Per Basic Share | -$1.00 | -$1.26 | -$3.82 | -$4.73 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 | Q3 2016 | Q2 2016 | Q1 2016 | Q4 2015 | Q3 2015 | Q2 2015 | Q1 2015 | Q4 2014 | Q3 2014 | Q2 2014 | Q1 2014 | Q4 2013 | Q3 2013 | Q2 2013 | Q1 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | $61.0M | $3.6M | $54.8M | -$13.6M | -$15.5M | -$12.7M | -$16.5M | -$11.7M | -$8.5M | -$9.0M | -$15.6M | -$22.1M | -$10.4M | $916.6M | -$8.2M | -$25.9M | -$32.0M | -$35.3M | -$52.4M | -$79.7M | -$58.4M | -$73.6M | -$62.9M | -$83.1M | -$65.6M | -$58.4M | -$39.8M | -$72.6M | -$50.2M | -$59.4M | -$40.8M | -$65.1M | -$86.9M | -$66.9M | -$66.3M | -$65.3M | -$67.3M | -$34.0M | -$47.2M | -$42.2M | -$44.8M | -$47.3M | -$47.6M | -$42.5M | -$64.3M | -$54.5M | -$58.2M | -$60.0M | -$44.1M | -$41.1M | -$39.0M | -$32.2M |
| Revenue * | $45.9M | $20.0M | $26.2M | $15.4M | $18.8M | $16.9M | $14.3M | $14.5M | $17.6M | $15.7M | $13.7M | $10.4M | $14.6M | $12.5M | $11.1M | $13.2M | $14.9M | $13.2M | $12.9M | $14.3M | $18.7M | $18.3M | $15.0M | $19.9M | $29.5M | $12.4M | $26.2M | $5.3M | $15.7M | $12.8M | $23.5M | $8.3M | $4.5M | $4.3M | $3.5M | $3.1M | $5.7M | $19.1M | $5.5M | $18.4M | $3.9M | $10.7M | $7.1M | $20.4M | $1.4M | $6.3M | $3.0M | $945.0K | $175.0K | $24.0K | $5.0K | $22.0K |
| Operating Expenses | $25.9M | $26.4M | $28.9M | $29.8M | $28.0M | $27.7M | $30.0M | $25.7M | $23.8M | $24.5M | $29.9M | $35.3M | $32.1M | $21.6M | $37.9M | $51.7M | $71.1M | $66.8M | $77.0M | $98.1M | $95.2M | $94.9M | $87.2M | $92.3M | $100.1M | $77.6M | $68.6M | $79.0M | $78.4M | $75.3M | $72.2M | $73.3M | $83.7M | $61.3M | $68.6M | $61.9M | $63.5M | $52.6M | $53.0M | $60.1M | $59.7M | $53.8M | $52.4M | $58.1M | $67.2M | $56.4M | $59.7M | $61.0M | $44.3M | $41.1M | $39.0M | $32.2M |
| Operating Income Loss | $20.0M | -$6.5M | -$2.7M | -$14.4M | -$9.2M | -$10.8M | -$15.7M | -$11.2M | -$6.2M | -$8.8M | -$16.1M | -$24.9M | -$17.4M | -$9.1M | -$26.9M | -$38.5M | -$56.2M | -$53.6M | -$64.1M | -$83.9M | -$76.5M | -$76.6M | -$72.2M | -$72.5M | -$70.6M | -$65.2M | -$42.5M | -$73.7M | -$62.6M | -$62.5M | -$48.7M | -$65.0M | -$79.2M | -$57.0M | -$65.1M | -$58.8M | -$57.8M | -$33.5M | -$47.5M | -$41.6M | -$55.8M | -$43.1M | -$45.3M | -$37.7M | -$65.8M | -$50.1M | -$56.7M | -$60.0M | -$44.1M | -$41.1M | -$39.0M | -$32.2M |
| Selling General And Administrative Expense | $18.3M | $18.4M | $18.4M | $16.9M | $17.1M | $16.7M | $16.1M | $19.3M | $19.2M | $16.3M | $16.2M | $17.8M | $21.3M | $25.9M | $30.6M | $27.5M | $24.8M | $26.3M | $25.6M | $22.2M | $25.2M | $21.9M | $25.0M | $24.7M | $20.9M | $24.3M | $20.8M | $20.3M | $20.3M | $23.6M | $22.8M | $21.5M | $21.7M | $17.7M | $13.1M | $19.1M | $8.8M | $8.6M | $6.8M | |||||||||||||
| Research And Development Expense | $8.1M | $10.5M | $11.5M | $9.3M | $10.0M | $9.0M | $8.3M | $9.4M | $14.6M | $9.9M | $14.9M | $23.3M | $43.7M | $51.1M | $67.6M | $67.4M | $62.4M | $66.0M | $52.0M | $46.4M | $53.8M | $52.7M | $48.6M | $47.8M | $39.3M | $42.9M | $40.6M | $32.0M | $32.1M | $35.7M | $30.4M | $30.4M | $36.0M | $38.3M | $46.3M | $41.7M | $32.3M | $30.4M | $25.4M | |||||||||||||
| Comprehensive Income Net Of Tax | $3.7M | $54.8M | -$13.6M | -$12.6M | -$16.5M | -$11.6M | -$8.9M | -$16.0M | -$22.0M | $916.6M | -$8.2M | -$26.0M | -$35.3M | -$52.4M | -$79.7M | -$73.8M | -$63.1M | -$82.7M | -$58.5M | -$39.7M | -$72.5M | -$59.2M | -$40.5M | -$65.2M | -$66.9M | -$66.3M | -$65.3M | -$34.1M | -$47.2M | -$42.0M | -$47.3M | -$47.6M | -$42.4M | -$54.6M | -$58.2M | -$60.0M | -$41.1M | -$39.0M | -$32.2M | |||||||||||||
| Other Nonoperating Income Expense | $4.1M | $1.5M | $939.0K | $1.4M | $1.1M | $1.4M | $1.8M | $2.5M | $3.0M | $2.8M | $2.4M | -$375.0K | -$166.0K | $1.2M | -$234.0K | $1.2M | -$662.0K | $1.5M | $2.1M | $2.4M | $2.8M | $1.4M | $1.3M | $1.5M | $1.1M | $1.4M | $1.0M | $344.0K | $308.0K | $186.0K | $104.0K | $204.0K | $211.0K | $668.0K | $214.0K | $0.00 | $0.00 | $0.00 | ||||||||||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$2.9M | $73.2M | -$14.1M | -$10.1M | -$15.2M | -$10.4M | -$7.6M | -$14.2M | -$22.5M | -$16.0M | -$22.8M | -$39.7M | -$55.9M | -$52.6M | -$79.5M | -$73.6M | -$62.8M | -$82.9M | -$64.0M | -$39.6M | -$72.5M | -$60.1M | -$47.6M | -$64.9M | -$66.0M | -$65.8M | -$59.9M | -$33.2M | -$47.2M | -$41.5M | -$43.0M | -$45.1M | -$37.5M | -$49.4M | -$56.5M | -$60.0M | -$41.1M | -$39.0M | ||||||||||||||
| Income Tax Expense Benefit | -$6.5M | $18.4M | -$559.0K | $2.6M | $1.3M | $1.3M | $1.4M | $1.5M | -$395.0K | -$5.0K | $524.0K | -$7.0K | -$220.0K | $227.0K | $93.0K | $39.0K | $147.0K | -$5.6M | $201.0K | $80.0K | -$659.0K | -$6.8M | $144.0K | $868.0K | $454.0K | $5.4M | $812.0K | $36.0K | $694.0K | $4.3M | $2.5M | $4.9M | $5.1M | $1.7M | $0.00 | $0.00 | $0.00 | |||||||||||||||
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $42.0K | -$10.0K | -$7.0K | $72.0K | $19.0K | $24.0K | $61.0K | -$337.0K | $66.0K | -$76.0K | -$17.0K | -$28.0K | $6.0K | -$9.0K | -$30.0K | -$158.0K | -$232.0K | $367.0K | -$35.0K | $165.0K | $130.0K | $194.0K | $329.0K | -$120.0K | -$44.0K | $24.0K | -$19.0K | -$142.0K | $55.0K | $196.0K | $19.0K | -$7.0K | $113.0K | -$97.0K | ||||||||||||||||||
| Interest Expense | $629.0K | $609.0K | $568.0K | $550.0K | $1.5M | $2.1M | $2.1M | $2.1M | $11.6M | $11.9M | $11.6M | $11.4M | $9.9M | $8.1M | $7.9M | $7.9M | $2.1M | $2.1M | $2.1M | $2.1M | $2.1M | $2.1M | $0.00 | $0.00 | $0.00 | |||||||||||||||||||||||||||
| Income Taxes Paid Net | $4.0K | -$9.0K | $7.0K | -$9.0K | $4.5M | $0.00 | $9.5M | |||||||||||||||||||||||||||||||||||||||||||||
| Cost Of Goods Sold | $985.0K | $1.4M | $565.0K | $332.0K | $638.0K | $778.0K | $581.0K | $505.0K | $371.0K | $369.0K | $279.0K | $188.0K | $0.00 | $0.00 | $0.00 | |||||||||||||||||||||||||||||||||||||
| Income Loss From Continuing Operations Per Diluted Share | -$0.17 | -$0.17 | -$0.28 | -$0.35 | -$0.21 | -$0.21 | -$0.35 | -$0.55 | -$0.78 | -$0.76 | -$0.99 | -$1.35 | ||||||||||||||||||||||||||||||||||||||||
| Income Loss From Continuing Operations Per Basic Share | -$0.17 | -$0.17 | -$0.28 | -$0.35 | -$0.21 | -$0.21 | -$0.35 | -$0.55 | -$0.78 | -$0.76 | -$0.99 | -$1.35 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $296.7M | $175.5M | $213.0M | $441.8M | -$338.6M | -$303.8M | -$223.8M | -$51.6M | $115.2M | $350.2M | $243.1M | $289.8M | -$17.0M | -$7.0M | -$140.7M |
| Cash And Cash Equivalents At Carrying Value | $167.8M | $37.8M | $39.5M | $298.2M | $90.0M | $81.5M | $58.1M | $378.0M | $89.0M | $344.7M | $112.7M | $89.2M | $0.00 | $0.00 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $168.6M | $38.6M | $40.4M | $299.0M | $90.8M | $82.3M | $58.9M | $378.9M | $89.8M | $345.5M | $113.5M | ||||
| Property Plant And Equipment Net | $5.9M | $7.4M | $9.1M | $11.9M | $13.7M | $16.4M | $12.6M | $13.2M | $10.2M | $8.5M | $9.9M | $9.7M | $10.2M | ||
| Liabilities Current | $38.3M | $32.1M | $24.8M | $28.7M | $58.6M | $123.6M | $111.7M | $98.6M | $62.6M | $49.3M | $49.5M | $41.3M | $36.9M | ||
| Liabilities And Stockholders Equity | $485.6M | $354.2M | $382.0M | $607.4M | $374.8M | $469.1M | $408.8M | $560.2M | $441.4M | $639.3M | $300.1M | $337.8M | $25.2M | ||
| Employee Related Liabilities Current | $12.6M | $7.0M | $6.4M | $10.3M | $12.8M | $35.2M | $28.2M | $23.8M | $24.1M | $14.0M | $10.9M | $18.2M | $9.9M | ||
| Assets Current | $418.5M | $161.1M | $133.5M | $353.5M | $249.9M | $393.3M | $338.5M | $532.8M | $378.7M | $528.5M | $237.5M | $275.4M | $14.1M | ||
| Assets | $485.6M | $354.2M | $382.0M | $607.4M | $374.8M | $469.1M | $408.8M | $560.2M | $441.4M | $639.3M | $300.1M | $337.8M | $25.2M | ||
| Accounts Payable Current | $2.6M | $2.2M | $1.5M | $1.6M | $3.1M | $6.8M | $4.8M | $9.0M | $5.9M | $1.7M | $18.8M | $9.9M | $6.9M | ||
| Retained Earnings Accumulated Deficit | -$859.6M | -$965.5M | -$909.1M | -$853.9M | -$1.73B | -$1.53B | -$1.25B | -$1.01B | -$797.7M | -$512.2M | -$321.6M | -$139.3M | $0.00 | ||
| Receivables From Collaboration Partners | $45.5M | $18.4M | $17.5M | $16.8M | $14.1M | $15.9M | $12.0M | $10.1M | $7.1M | $9.1M | $35.2M | $1.8M | $934.0K | ||
| Available For Sale Securities Debt Securities Current | $147.6M | $50.6M | $62.9M | $29.3M | $83.5M | $211.5M | $222.8M | $127.3M | $259.6M | $156.4M | $59.7M | $165.4M | $0.00 | ||
| Other Liabilities Noncurrent | $313.0K | $1.9M | $5.9M | $1.7M | $2.2M | $1.8M | $21.3M | $24.8M | $34.8M | $13.1M | $3.0M | $1.6M | $585.0K | ||
| Other Assets Noncurrent | $24.9M | $12.3M | $8.1M | $6.9M | $3.2M | $2.5M | $1.6M | $1.5M | $1.9M | $1.9M | $1.1M | $506.0K | $0.00 | ||
| Other Accrued Liabilities Current | $1.5M | $2.2M | $1.2M | $1.1M | $1.3M | $2.0M | $1.9M | $7.4M | $11.7M | $8.3M | $4.9M | $5.2M | $9.7M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $61.0K | $7.0K | -$65.0K | -$15.0K | $47.0K | $145.0K | -$166.0K | -$733.0K | -$253.0K | -$70.0K | -$82.0K | $0.00 | |||
| Accrued Clinical And Development Expenses Current | $3.4M | $1.1M | $2.2M | $4.9M | $17.0M | $28.8M | $17.6M | $11.9M | $20.7M | $25.1M | $14.7M | $7.9M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $130.0M | -$1.7M | -$258.6M | $208.2M | $8.5M | $23.4M | -$320.0M | $289.0M | -$255.7M | $232.0M | |||||
| Common Stock Value | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |||||||
| Available For Sale Securities Debt Securities Noncurrent | $11.1M | $5.0M | $11.9M | $41.6M | $91.6M | $42.9M | $51.4M | $0.00 | |||||||
| Restricted Cash Noncurrent | $836.0K | $836.0K | $836.0K | $836.0K | $837.0K | $833.0K | $833.0K | $833.0K | |||||||
| Operating Lease Right Of Use Asset | $24.4M | $28.4M | $36.3M | $40.1M | $39.7M | $43.3M | $46.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 | Q3 2017 | Q2 2017 | Q1 2017 | Q3 2016 | Q2 2016 | Q1 2016 | Q3 2015 | Q2 2015 | Q1 2015 | Q3 2014 | Q2 2014 | Q1 2014 | Q3 2013 | Q2 2013 | Q1 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $232.7M | $224.8M | $166.0M | $185.7M | $193.7M | $204.9M | $213.0M | $246.1M | $280.2M | $370.6M | $480.6M | -$349.8M | -$351.5M | -$323.6M | -$300.4M | -$373.2M | -$261.5M | -$202.3M | -$157.9M | -$182.8M | -$137.2M | -$113.3M | -$13.4M | $34.4M | $63.4M | $184.1M | $241.1M | $293.9M | $297.9M | $321.6M | $238.5M | $222.5M | $257.7M | $289.1M | $339.8M | $384.8M | -$17.9M | |||
| Cash And Cash Equivalents At Carrying Value | $174.8M | $281.9M | $110.6M | $23.4M | $46.3M | $53.8M | $71.7M | $105.6M | $187.7M | $418.5M | $87.3M | $94.4M | $121.4M | $204.9M | $114.0M | $93.3M | $104.7M | $332.8M | $102.4M | $178.3M | $223.2M | $101.2M | $103.9M | $125.8M | $91.3M | $139.6M | $169.9M | $86.6M | $148.4M | $128.8M | $127.1M | $97.1M | $100.9M | $122.2M | $268.2M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $175.6M | $282.8M | $111.5M | $24.2M | $47.2M | $54.7M | $72.5M | $106.4M | $188.5M | $419.4M | $88.1M | $95.2M | $122.3M | $205.8M | $114.8M | $94.1M | $105.6M | $333.6M | $110.7M | $179.1M | $224.1M | $102.0M | $104.7M | $126.7M | $92.1M | $140.5M | $170.8M | |||||||||||||
| Property Plant And Equipment Net | $6.3M | $6.6M | $7.0M | $7.8M | $8.1M | $8.7M | $9.3M | $9.6M | $12.1M | $11.9M | $12.5M | $13.2M | $16.0M | $16.6M | $16.9M | $15.4M | $14.4M | $13.9M | $12.2M | $12.7M | $12.9M | $12.4M | $10.7M | $10.3M | $8.6M | $8.7M | $8.3M | $8.8M | $8.8M | $10.1M | $9.5M | $9.6M | $9.3M | $9.4M | $9.6M | $9.7M | ||||
| Liabilities Current | $37.4M | $54.6M | $31.5M | $23.4M | $22.9M | $21.7M | $25.4M | $24.5M | $26.2M | $142.1M | $32.6M | $44.2M | $66.1M | $67.1M | $86.5M | $104.3M | $106.6M | $98.0M | $108.8M | $110.1M | $113.5M | $102.0M | $93.5M | $105.2M | $48.8M | $57.1M | $49.0M | $45.4M | $44.7M | $46.4M | $27.4M | $24.5M | $28.9M | $35.8M | $40.1M | $38.5M | ||||
| Liabilities And Stockholders Equity | $415.5M | $426.0M | $343.6M | $356.1M | $362.0M | $371.3M | $413.6M | $446.6M | $538.6M | $763.5M | $360.8M | $355.4M | $403.1M | $429.3M | $375.1M | $512.2M | $564.3M | $605.4M | $445.3M | $492.4M | $531.3M | $371.0M | $421.4M | $480.1M | $486.2M | $543.9M | $588.0M | $356.3M | $374.5M | $293.1M | $257.5M | $289.5M | $324.9M | $381.7M | $430.6M | $26.2M | ||||
| Employee Related Liabilities Current | $10.3M | $7.3M | $5.4M | $7.8M | $5.8M | $4.5M | $6.6M | $5.4M | $5.0M | $7.6M | $7.0M | $9.6M | $8.6M | $14.6M | $15.6M | $30.5M | $26.8M | $24.7M | $25.8M | $23.5M | $22.1M | $15.9M | $12.2M | $22.0M | $12.7M | $15.8M | $9.1M | $11.9M | $9.0M | $7.8M | $10.2M | $7.8M | $10.4M | $10.9M | $6.5M | $13.4M | ||||
| Assets Current | $354.7M | $366.3M | $150.3M | $116.5M | $119.3M | $124.3M | $161.7M | $192.0M | $261.3M | $511.7M | $154.7M | $204.6M | $297.2M | $333.2M | $293.1M | $450.7M | $498.4M | $534.2M | $355.7M | $426.0M | $467.2M | $332.6M | $386.7M | $446.8M | $367.1M | $384.9M | $421.5M | $274.0M | $303.1M | $238.8M | $238.2M | $260.2M | $275.6M | $306.7M | $382.7M | $15.6M | ||||
| Assets | $415.5M | $426.0M | $343.6M | $356.1M | $362.0M | $371.3M | $413.6M | $446.6M | $538.6M | $763.5M | $360.8M | $355.4M | $403.1M | $429.3M | $375.1M | $512.2M | $564.3M | $605.4M | $445.3M | $492.4M | $531.3M | $371.0M | $421.4M | $480.1M | $486.2M | $543.9M | $588.0M | $356.3M | $374.5M | $293.1M | $257.5M | $289.5M | $324.9M | $381.7M | $430.6M | $26.2M | ||||
| Accounts Payable Current | $2.2M | $1.7M | $2.4M | $1.5M | $1.7M | $1.7M | $2.4M | $1.6M | $2.7M | $5.3M | $3.1M | $1.5M | $8.9M | $10.7M | $6.8M | $6.4M | $10.1M | $6.6M | $8.7M | $3.5M | $5.6M | $3.7M | $3.6M | $5.1M | $5.6M | $6.4M | $3.6M | $5.4M | $7.4M | $9.1M | $6.0M | $6.3M | $4.0M | $5.3M | $9.5M | $5.0M | ||||
| Retained Earnings Accumulated Deficit | -$920.7M | -$924.3M | -$979.1M | -$950.0M | -$937.3M | -$920.8M | -$900.6M | -$891.6M | -$876.0M | -$843.5M | -$1.76B | -$1.75B | -$1.69B | -$1.66B | -$1.61B | -$1.47B | -$1.39B | -$1.33B | -$1.18B | -$1.12B | -$1.08B | -$962.0M | -$902.5M | -$861.7M | -$710.8M | -$643.9M | -$577.7M | -$444.9M | -$410.9M | -$363.7M | -$276.7M | -$229.4M | -$181.8M | -$75.0M | -$20.5M | |||||
| Receivables From Collaboration Partners | $18.3M | $21.9M | $15.4M | $16.8M | $14.3M | $14.7M | $17.1M | $15.8M | $12.3M | $14.1M | $12.5M | $12.3M | $14.0M | $12.2M | $11.9M | $12.4M | $11.4M | $14.2M | $4.6M | $979.0K | $7.8M | $3.9M | $3.9M | $2.8M | $11.5M | $5.3M | $7.6M | $22.7M | $35.1M | $37.5M | $19.6M | $25.5M | $19.7M | $181.0K | $2.0K | |||||
| Available For Sale Securities Debt Securities Current | $154.9M | $56.9M | $20.2M | $68.0M | $49.7M | $46.1M | $62.3M | $61.9M | $53.6M | $68.3M | $45.6M | $53.1M | $94.8M | $60.0M | $96.0M | $265.1M | $333.6M | $154.2M | $217.3M | $217.8M | $210.8M | $199.2M | $249.0M | $292.7M | $243.7M | $222.2M | $222.8M | $143.9M | $101.3M | $51.1M | $68.9M | $113.9M | $135.3M | $162.5M | $81.0M | |||||
| Other Liabilities Noncurrent | $313.0K | $1.5M | $1.3M | $5.0M | $4.9M | $5.4M | $7.7M | $7.7M | $7.7M | $1.7M | $2.4M | $2.4M | $2.6M | $1.8M | $2.1M | $9.7M | $9.6M | $9.6M | $8.9M | $14.5M | $14.3M | $28.3M | $28.3M | $36.1M | $26.5M | $19.0M | $18.5M | $8.8M | $3.9M | $3.7M | $2.8M | $2.4M | $1.9M | $986.0K | ||||||
| Other Assets Noncurrent | $25.2M | $25.8M | $13.8M | $7.5M | $7.7M | $7.9M | $10.0M | $11.6M | $12.1M | $4.9M | $3.3M | $3.2M | $3.3M | $1.3M | $2.3M | $810.0K | $1.5M | $1.3M | $1.3M | $1.4M | $1.4M | $1.8M | $1.8M | $1.8M | $2.1M | $5.0M | $1.6M | $5.8M | $1.4M | $823.0K | $921.0K | $1.0M | $686.0K | |||||||
| Other Accrued Liabilities Current | $1.3M | $1.9M | $2.1M | $1.2M | $864.0K | $1.1M | $1.5M | $1.5M | $1.4M | $142.0K | $2.3M | $792.0K | $1.8M | $1.5M | $1.8M | $6.7M | $7.0M | $6.6M | $6.5M | $6.4M | $15.6M | $11.1M | $8.7M | $11.5M | $9.8M | $8.4M | $8.0M | $4.1M | $4.9M | $4.7M | $9.4M | $13.9M | $9.9M | |||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $32.0K | -$10.0K | $50.0K | -$22.0K | -$41.0K | -$225.0K | -$286.0K | $51.0K | -$121.0K | -$45.0K | -$28.0K | $14.0K | $8.0K | $17.0K | $122.0K | $280.0K | $512.0K | $94.0K | $129.0K | -$36.0K | -$331.0K | -$525.0K | -$854.0K | -$292.0K | -$248.0K | -$272.0K | $39.0K | $181.0K | $126.0K | $43.0K | $25.0K | $31.0K | -$27.0K | $70.0K | ||||||
| Accrued Clinical And Development Expenses Current | $5.8M | $3.8M | $2.5M | $864.0K | $2.0M | $1.4M | $3.3M | $4.0M | $5.0M | $4.1M | $7.6M | $8.9M | $20.6M | $19.5M | $30.9M | $26.9M | $25.2M | $22.7M | $10.9M | $7.4M | $9.2M | $14.1M | $14.5M | $16.4M | $20.5M | $26.4M | $28.0M | $23.9M | $22.7M | $23.6M | $6.7M | $6.7M | $6.6M | |||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $72.8M | $14.3M | -$110.5M | $4.4M | $32.5M | $274.7M | -$154.8M | $36.9M | -$174.8M | |||||||||||||||||||||||||||||||
| Common Stock Value | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | ||||||||||||||||
| Available For Sale Securities Debt Securities Noncurrent | $3.0M | $18.8M | $5.1M | $24.9M | $20.2M | $18.3M | $17.0M | $99.4M | $136.4M | $147.9M | $58.8M | $52.3M | $34.6M | $0.00 | $17.8M | $38.5M | $65.6M | $38.2M | ||||||||||||||||||||||
| Restricted Cash Noncurrent | $836.0K | $836.0K | $836.0K | $836.0K | $836.0K | $836.0K | $836.0K | $836.0K | $836.0K | $836.0K | $836.0K | $836.0K | $833.0K | $833.0K | $833.0K | $833.0K | $833.0K | $833.0K | $833.0K | |||||||||||||||||||||
| Operating Lease Right Of Use Asset | $25.5M | $26.5M | $27.4M | $29.3M | $31.8M | $35.4M | $37.6M | $38.5M | $39.2M | $40.0M | $41.1M | $39.3M | $40.7M | $41.5M | $42.5M | $44.4M | $45.2M | $46.1M | $46.8M | $47.8M | $48.9M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share-Based Compensation * | $18.5M | $21.4M | $25.4M | $39.7M | $62.1M | $63.0M | $60.5M | $51.3M | $49.1M | $41.2M | $54.1M | $43.2M | $22.5M | $21.3M |
| Financing Cash Flow * | -$3.2M | -$2.5M | -$198.9M | -$758.8M | $91.9M | $263.1M | $1.3M | $225.2M | $1.7M | $479.2M | $81.3M | $370.6M | $123.6M | $121.5M |
| Investing Cash Flow * | -$105.3M | $12.3M | -$32.7M | $1.15B | $124.5M | $10.7M | -$83.1M | $176.7M | -$56.3M | -$148.2M | $111.0M | -$106.3M | -$2.6M | -$2.4M |
| Operating Cash Flow * | $238.5M | -$11.5M | -$27.0M | -$187.0M | -$207.9M | -$250.4M | -$238.2M | -$112.9M | -$201.1M | -$99.0M | -$168.9M | -$175.2M | -$121.0M | -$119.1M |
| Increase Decrease In Accrued Liabilities | $4.0M | $1.5M | -$7.1M | -$14.1M | -$37.2M | $6.0M | $10.6M | -$12.4M | $8.3M | $17.2M | -$1.0M | $11.7M | $4.2M | -$1.7M |
| Increase Decrease In Accounts Payable | $326.0K | $750.0K | $6.0K | -$1.6M | -$3.5M | $3.7M | -$4.3M | $3.6M | $3.8M | -$16.4M | $8.7M | $3.9M | $2.1M | -$1.5M |
| Proceeds From Sale And Maturity Of Available For Sale Securities | $143.0M | $139.8M | $31.4M | $158.0M | $286.2M | $399.3M | $339.0M | $347.2M | $234.9M | $91.5M | $186.7M | $65.6M | $0.00 | $0.00 |
| Adjustments Related To Tax Withholding For Share Based Compensation | $4.0M | $2.7M | $2.5M | $3.5M | $9.1M | $9.7M | $3.2M | $9.8M | $8.6M | $3.9M | $756.0K | $178.0K | ||
| Increase Decrease In Other Noncurrent Liabilities | $67.0K | -$532.0K | $7.5M | -$525.0K | $777.0K | $936.0K | -$4.7M | -$10.1M | $24.4M | $9.7M | $1.2M | $866.0K | $0.00 | $0.00 |
| Increase Decrease In Receivables From Collaboration Partners | $27.1M | $966.0K | $689.0K | $2.7M | -$1.8M | -$6.1M | $11.9M | $2.9M | -$2.0M | -$26.2M | $33.4M | $906.0K | -$7.0K | |
| Payments Related To Tax Withholding For Share Based Compensation | $4.0M | $2.7M | $2.5M | $3.5M | $9.1M | $9.7M | $3.2M | $9.8M | $8.6M | $3.9M | $756.0K | $178.0K | $0.00 | $0.00 |
| Increase Decrease In Other Operating Assets | $1.1M | -$411.0K | $1.2M | $3.8M | $972.0K | $1.1M | $358.0K | -$45.0K | $354.0K | -$184.0K | $572.0K | $211.0K | $0.00 | $0.00 |
| Increase Decrease In Prepaid Expenses Other | $3.4M | -$7.4M | $3.9M | $704.0K | -$2.9M | $2.3M | $73.0K | $225.0K | $1.5M | -$2.7M | -$963.0K | $2.9M | -$19.0K | |
| Payments To Acquire Productive Assets | $42.0K | $332.0K | $2.5M | $572.0K | $3.4M | $6.6M | $3.2M | $7.2M | $2.4M | $2.1M | $2.6M | |||
| Payments To Acquire Available For Sale Securities Debt | $248.2M | $140.7M | $134.5M | $103.1M | $158.3M | $402.0M | $423.9M | $183.3M | $288.8M | $237.6M | ||||
| Proceeds From Stock Plans | $508.0K | $618.0K | $802.0K | $3.5M | $3.7M | $3.5M | $4.2M | $4.0M | $3.2M | $3.1M | $0.00 | $0.00 | ||
| Increase Decrease In Accounts Receivable | -$620.0K | -$1.6M | $1.6M | -$1.3M | $1.6M | $90.0K | $199.0K | $0.00 | ||||||
| Proceeds From Stock Options Exercised | $766.0K | $5.0K | $1.4M | $3.1M | $1.4M | $6.2M | $4.4M | $0.00 | $0.00 | |||||
| Increase Decrease In Contract With Customer Liability | -$216.0K | -$192.0K | -$11.5M | -$26.5M | -$31.2M | $69.2M | $17.0K | $448.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 | Q3 2017 | Q2 2017 | Q1 2017 | Q3 2016 | Q2 2016 | Q1 2016 | Q3 2015 | Q2 2015 | Q1 2015 | Q3 2014 | Q1 2014 | Q1 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share-Based Compensation * | $4.6M | $4.5M | $4.9M | $5.0M | $5.4M | $5.2M | $6.3M | $6.3M | $7.0M | $8.5M | $9.7M | $14.5M | $14.4M | $14.9M | $15.8M | $15.6M | $16.6M | $15.3M | $13.0M | $11.3M | $12.2M | $11.7M | $13.9M | $14.0M | $10.7M | $10.4M | $10.3M | $9.9M | $9.9M | $11.3M | $12.3M | $14.7M | $15.6M | $9.4M | $12.7M | $5.5M |
| Financing Cash Flow * | -$854.0K | -$1.7M | -$56.2M | -$1.4M | -$11.3M | $261.4M | -$1.4M | -$1.7M | -$1.2M | $26.0M | $26.0M | $46.4M | $29.1M | |||||||||||||||||||||||
| Investing Cash Flow * | $30.6M | $17.0M | -$43.0M | $31.9M | $113.7M | $68.4M | -$72.2M | -$11.3M | -$123.5M | $16.4M | $42.2M | -$1.6M | -$640.0K | |||||||||||||||||||||||
| Operating Cash Flow * | $43.0M | -$1.0M | -$11.2M | -$26.1M | -$69.9M | -$55.1M | -$81.2M | $49.8M | -$50.0M | -$26.3M | -$56.5M | -$44.8M | -$28.5M | |||||||||||||||||||||||
| Increase Decrease In Accrued Liabilities | -$1.5M | -$3.4M | -$4.3M | -$10.3M | -$17.3M | -$10.5M | -$2.7M | -$5.1M | -$3.2M | $5.7M | -$6.2M | $4.6M | -$3.7M | |||||||||||||||||||||||
| Increase Decrease In Accounts Payable | $166.0K | $184.0K | $1.0M | -$1.6M | -$1.1M | $1.2M | -$3.4M | -$449.0K | $2.0M | -$9.5M | -$5.4M | -$1.1M | -$150.0K | |||||||||||||||||||||||
| Proceeds From Sale And Maturity Of Available For Sale Securities | $32.6M | $44.0M | $29.5M | $48.5M | $115.5M | $119.2M | $77.2M | $46.3M | $36.3M | $17.1M | $53.5M | $0.00 | ||||||||||||||||||||||||
| Adjustments Related To Tax Withholding For Share Based Compensation | $678.0K | $503.0K | $874.0K | $397.0K | $464.0K | $1.3M | $512.0K | $583.0K | $887.0K | $662.0K | $347.0K | $1.4M | $2.3M | $727.0K | $5.6M | $987.0K | $1.1M | $6.8M | $562.0K | $494.0K | $1.7M | $1.5M | $5.2M | $1.7M | ||||||||||||
| Increase Decrease In Other Noncurrent Liabilities | $68.0K | $39.0K | -$468.0K | $8.0K | $224.0K | $144.0K | $73.0K | $1.3M | $5.4M | $590.0K | $321.0K | $0.00 | ||||||||||||||||||||||||
| Increase Decrease In Receivables From Collaboration Partners | -$3.1M | -$2.8M | -$4.5M | -$1.8M | -$4.0M | -$6.6M | -$2.2M | -$4.3M | -$1.4M | $2.3M | $17.8M | -$844.0K | ||||||||||||||||||||||||
| Payments Related To Tax Withholding For Share Based Compensation | $874.0K | $1.3M | $887.0K | $1.4M | $5.6M | $6.8M | $1.7M | $1.7M | $4.0M | $1.8M | $100.0K | $0.00 | ||||||||||||||||||||||||
| Increase Decrease In Other Operating Assets | -$330.0K | -$148.0K | -$1.3M | -$1.0K | -$65.0K | $99.0K | -$266.0K | -$255.0K | $180.0K | $0.00 | ||||||||||||||||||||||||||
| Increase Decrease In Prepaid Expenses Other | -$148.0K | -$4.0M | -$1.4M | -$2.4M | -$322.0K | -$1.6M | $2.1M | $1.6M | $1.2M | $5.1M | $664.0K | |||||||||||||||||||||||||
| Payments To Acquire Productive Assets | $91.0K | $938.0K | $250.0K | $1.8M | $954.0K | $1.2M | $2.8M | $587.0K | $684.0K | |||||||||||||||||||||||||||
| Payments To Acquire Available For Sale Securities Debt | $2.0M | $26.9M | $134.5M | $18.2M | $36.0K | $64.8M | $148.1M | $54.8M | $159.2M | |||||||||||||||||||||||||||
| Proceeds From Stock Plans | ||||||||||||||||||||||||||||||||||||
| Increase Decrease In Accounts Receivable | -$507.0K | -$280.0K | $587.0K | -$395.0K | $276.0K | -$196.0K | $0.00 | |||||||||||||||||||||||||||||
| Proceeds From Stock Options Exercised | $3.0K | $203.0K | $254.0K | $35.0K | $2.8M | $0.00 | ||||||||||||||||||||||||||||||
| Increase Decrease In Contract With Customer Liability | -$6.0K | -$9.0K | -$3.9M | -$6.6M | -$5.3M | $95.4M | $17.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | $2.06 | -$1.15 | -$1.00 | $11.85 | -$2.87 | -$4.46 | -$4.25 | -$3.99 | -$5.45 | -$4.26 | -$5.34 | -$7.46 | -$4.92 | -$0.30 |
| Earnings Per Share Basic | $2.10 | $-1.15 | $-1.00 | $11.85 | $-2.87 | $-4.46 | $-4.25 | |||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 62.3M | 55.6M | 54.0M | 52.4M | 44.7M | 34.2M | 31.8M | 31.7M | 31.7M | |||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Preferred Stock Shares Authorized | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 0.00 | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Outstanding | 51.1M | 49.5M | 48.1M | 65.2M | 74.4M | 64.3M | 57.0M | 55.7M | 54.4M | 52.8M | 38.0M | 32.2M | 0.00 | |
| Common Stock Shares Issued | 51.1M | 49.5M | 48.1M | 65.2M | 74.4M | 64.3M | 57.0M | 55.7M | 54.4M | 52.8M | 38.0M | 32.2M | 0.00 | |
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 0.00 | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Number Of Shares Outstanding Basic | 50.3M | 48.8M | 55.3M | 73.6M | 69.5M | 62.3M | 55.6M | |||||||
| Weighted Average Number Of Diluted Shares Outstanding | 51.5M | 48.8M | 55.3M | 73.6M | 69.5M | 62.3M | 55.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 | Q3 2016 | Q2 2016 | Q1 2016 | Q4 2015 | Q3 2015 | Q2 2015 | Q1 2015 | Q4 2014 | Q3 2014 | Q2 2014 | Q1 2014 | Q4 2013 | Q3 2013 | Q2 2013 | Q1 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | $1.15 | $0.07 | $1.08 | -$0.27 | -$0.31 | -$0.26 | -$0.34 | -$0.24 | -$0.17 | -$0.17 | -$0.28 | -$0.35 | -$0.15 | $12.14 | -$0.11 | -$0.34 | -$0.43 | -$0.48 | -$0.80 | -$1.24 | -$0.92 | -$1.16 | -$1.00 | -$1.40 | -$1.17 | -$1.05 | -$0.72 | -$1.32 | -$0.92 | -$1.10 | -$0.76 | -$1.22 | -$1.64 | -$1.27 | -$1.27 | -$1.27 | -$1.36 | -$0.73 | -$1.06 | -$1.10 | -$1.23 | -$1.40 | -$1.42 | -$1.29 | -$2.02 | -$1.72 | -$1.83 | -$1.89 | -$1.39 | -$1.29 | -$1.23 | -$1.01 |
| Earnings Per Share Basic | $1.20 | $0.07 | $1.09 | $-0.27 | $-0.31 | $-0.26 | $-0.34 | $-0.24 | $-0.17 | $-0.17 | $-0.28 | $-0.35 | $-0.15 | $12.14 | $-0.11 | $-0.34 | $-0.43 | $-0.48 | $-0.80 | $-1.24 | $-0.92 | $-1.16 | $-1.00 | $-1.40 | ||||||||||||||||||||||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 65.7M | 64.5M | 63.3M | 62.9M | 59.5M | 55.9M | 55.5M | 54.9M | 54.2M | 53.8M | 53.3M | 52.6M | 52.3M | 51.6M | 46.5M | 44.4M | 38.3M | 33.7M | 33.5M | 32.8M | 31.8M | 31.8M | 31.7M | 31.7M | 31.8M | |||||||||||||||||||||||||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| Preferred Stock Shares Authorized | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | 230.0K | |||||||||||||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||||||
| Common Stock Shares Outstanding | 50.7M | 50.4M | 50.0M | 49.2M | 48.9M | 48.6M | 50.8M | 53.7M | 60.5M | 67.4M | 76.4M | 76.1M | 73.7M | 73.5M | 65.2M | 64.0M | 63.5M | 63.0M | 56.8M | 56.6M | 56.1M | 55.4M | 55.1M | 54.8M | 54.1M | 53.8M | 53.3M | 48.1M | 47.9M | 41.5M | 33.9M | 33.9M | 33.8M | 32.2M | 32.3M | |||||||||||||||||
| Common Stock Shares Issued | 50.7M | 50.4M | 50.0M | 49.2M | 48.9M | 48.6M | 50.8M | 53.7M | 60.5M | 67.4M | 76.4M | 76.1M | 73.7M | 73.5M | 65.2M | 64.0M | 63.5M | 63.0M | 56.8M | 56.6M | 56.1M | 55.4M | 55.1M | 54.8M | 54.1M | 53.8M | 53.3M | 48.1M | 47.9M | 41.5M | 33.9M | 33.9M | 33.8M | 32.2M | 32.3M | |||||||||||||||||
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | |||||||||||||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||||||
| Weighted Average Number Of Shares Outstanding Basic | 50.5M | 50.2M | 49.7M | 49.0M | 48.7M | 48.3M | 52.4M | 56.7M | 62.9M | 75.5M | 76.3M | 75.2M | 73.6M | 65.7M | 64.5M | 63.3M | ||||||||||||||||||||||||||||||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 51.9M | 50.7M | 49.7M | 49.0M | 48.7M | 48.3M | 52.4M | 56.7M | 62.9M | 75.5M | 76.3M | 75.2M | 73.6M | 65.7M | 64.5M | 63.3M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $18.5M | $21.4M | $25.4M | $39.7M | $62.1M | $63.0M | $60.5M | $51.3M | $49.2M | $41.3M | $54.2M | $43.5M | $22.6M | |
| Additional Paid In Capital | $1.16B | $1.14B | $1.12B | $1.30B | $1.39B | $1.22B | $1.02B | $960.7M | $913.7M | $862.7M | $564.7M | $429.2M | $0.00 | |
| Other Prepaid Expense Current | $7.6M | $4.3M | $11.6M | $7.7M | $8.6M | $10.4M | $4.4M | $11.5M | $3.7M | $2.4M | $5.1M | $6.1M | ||
| Stock Issued During Period Value Employee Stock Purchase Plan | $20.0K | $508.0K | $619.0K | $802.0K | $3.5M | $3.7M | $3.5M | $4.2M | $4.0M | $3.2M | $3.1M | |||
| Other Noncash Income Expense | $89.0K | -$10.0K | $95.0K | -$146.0K | $43.0K | -$10.0K | -$182.0K | $65.0K | $0.00 | -$20.0K | -$196.0K | |||
| Amortization And Accretion Income | $2.8M | $2.5M | $1.9M | $681.0K | -$10.0K | $1.1M | $3.5M | $1.3M | -$226.0K | |||||
| Other Depreciation And Amortization | $1.6M | $1.7M | $2.0M | $3.7M | $4.8M | $4.7M | $6.4M | $4.5M | $3.8M | |||||
| Stock Issued During Period Value Stock Options Exercised | $766.0K | $5.0K | $1.4M | $3.1M | $1.4M | $6.2M | $4.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 | Q3 2017 | Q2 2017 | Q1 2017 | Q3 2016 | Q2 2016 | Q1 2016 | Q3 2015 | Q2 2015 | Q1 2015 | Q3 2014 | Q2 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $4.6M | $4.5M | $4.9M | $5.0M | $5.4M | $5.2M | $6.3M | $6.3M | $7.0M | $8.5M | $9.7M | $14.5M | $14.4M | $14.9M | $15.8M | $15.6M | $16.6M | $15.3M | $13.0M | $11.3M | $12.2M | $11.7M | $13.9M | $14.0M | |||||||||||
| Additional Paid In Capital | $1.15B | $1.15B | $1.15B | $1.14B | $1.13B | $1.13B | $1.15B | $1.17B | $1.25B | $1.32B | $1.41B | $1.40B | $1.37B | $1.36B | $1.23B | $1.21B | $1.19B | $1.17B | $1.00B | $987.2M | $971.5M | $948.8M | $937.4M | $926.0M | $895.2M | $885.3M | $871.9M | $742.7M | $732.3M | $602.1M | $499.2M | $487.1M | $470.9M | $414.9M | $405.2M |
| Other Prepaid Expense Current | $6.8M | $5.6M | $4.1M | $7.7M | $6.3M | $7.6M | $9.0M | $7.8M | $6.3M | $8.1M | $7.1M | $4.5M | $9.9M | $12.4M | $10.0M | $10.3M | $13.1M | $5.5M | $7.1M | $8.9M | $24.9M | $7.0M | $7.6M | $5.3M | $3.5M | $4.0M | $3.6M | $4.3M | $3.6M | $10.2M | |||||
| Stock Issued During Period Value Employee Stock Purchase Plan | $20.0K | $375.0K | $446.0K | $1.0K | $487.0K | $2.9M | $2.5M | $2.6M | $2.7M | ||||||||||||||||||||||||||
| Other Noncash Income Expense | $39.0K | -$46.0K | -$9.0K | -$16.0K | $397.0K | -$53.0K | $0.00 | ||||||||||||||||||||||||||||
| Amortization And Accretion Income | $327.0K | $354.0K | $678.0K | -$2.0K | -$11.0K | $536.0K | $629.0K | $107.0K | |||||||||||||||||||||||||||
| Other Depreciation And Amortization | $413.0K | $432.0K | $625.0K | $980.0K | $1.5M | $2.4M | $1.3M | ||||||||||||||||||||||||||||
| Stock Issued During Period Value Stock Options Exercised | $278.0K | $2.0K | $3.0K | $24.0K | $733.0K | $203.0K | $428.0K | $2.3M | $254.0K | $1.2M | $46.0K | $35.0K |
Most recent annual filing with the SEC: March 23, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.